Translational research, which aims to bring new discoveries to the clinic to help patients as quickly as possible, is the hallmark of the investigative efforts of RPCI’s Leukemia Team. It begins in the laboratory, where researchers define an aberration within a cell and strive to correct it, an endeavor that has led to the development of many medications we use today. RPCI researchers are investigating a number of pathways in leukemia, and this work has already led to several clinical studies for RPCI patients.
Currently we are investigating:
Vitamin D and Leukemia
Prior research at RPCI has indicated that low vitamin D levels are associated with poorer outcomes for acute myeloid leukemia. We are currently assessing the effect of vitamin D supplementation in this patient population.
Hematologic Procurement Facility
This facility allows RPCI to collect and bank tissue samples from all patients with hematologic malignancies. We study these samples to better understand characteristics of individual patients’ disease, and this leads to new findings and the development of better clinical studies for leukemia patients.